, the early stage technology fund set up by Cambridge innovation company TTP, has concluded investments in three new companies; Zynergy Group Ltd, ZBD Displays Ltd and Argenta Discovery Ltd (formerly ChemMedICa).
Hat-trick for TTP Ventures
Zynergy is a medical materials and devices company with facilities in both the UK and USA. Its initial products are catheters for keyhole procedures on the heart and vascular system. TTP led a syndicate of investors including NPM Capital of The Netherlands. Dr Christopher van Essen, who joins Zynergy's board, said, 'Zynergy's underlying polymer technology is excellent and their superior products should have considerable success in this growing market'.
ZBD Displays is the first venture capital backed spin out from DERA (the UK Defence Evaluation and Research Agency) and is developing a new form of liquid crystal display which will offer greater brightness and lower power consumption than existing technologies.
DERA is one of the world's leading research centres for LCDs and it is hoped that ZBD will become the display technology of choice for Personal Digital Assistants (PDAs) and other mobile devices.
Argenta Discovery Ltd (formerly ChemMedICa), TTP Ventures third investment, is in drug discovery technology and combines a management buyout of a top team of pharmaceuticals chemists from Aventis with a high level academic team from Imperial College.
Over the summer TTP Ventures also made two seed investments of less than 100,000 each in start-up companies involved in optoelectronics and mobile phone technology.
'We are delighted with the way the portfolio of our first fund is shaping up ' said David Connell, TTP Ventures' Chief Executive, 'and access to TTP Group plc's wide ranging expertise and contacts is proving a real boon to both entrepreneurs and fellow investors'.
TTP Ventures supports early stage technology companies with investment and incubation services.